Loading
NASDAQHealthcareBiotechnology
Latest quote
$13.14
−$0.04 · -0.30%
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Previous close
$13.14
−$0.04 · -0.30%
Pre-market
$13.39
+$0.25 · +1.90%
Oct 8, 4:33 AM ET
Regular session · ET · Market data may be delayed.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Day range
Current $13.14
52-week range
Current $13.14
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
57
Mixed
Risk
45
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Day range
Current $13.14
52-week range
Current $13.14
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 33.48M USD | 39.38M USD | 23.68M USD | 19.83M USD | 22.98M USD |
| Selling, general, and administrative | 15.85M USD | 12.15M USD | 10.24M USD | 10.07M USD | 9.49M USD |
| Operating expenses | 49.33M USD | 51.52M USD | 33.92M USD | 29.91M USD | 32.48M USD |
| Interest income | 6.54M USD | 3.6M USD | 4.75M USD | 1.74M USD | 10K USD |
| Interest expense | — | 4K USD | 391K USD | 780K USD | 1.2M USD |
| Depreciation and amortization | 144K USD | 147K USD | 123K USD | 43K USD | 50K USD |
| Operating income | −49.33M USD | −51.52M USD | −33.92M USD | −29.91M USD | −32.48M USD |
| Net income | −42.76M USD | −47.91M USD | −29.07M USD | −29.15M USD | −33.94M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$29.67
125.80% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI67.39M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM37.47M0.05%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF22.69M0.02%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO13.53M0.09%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO10.23M0.06%18B USD0.06%$112.21-1.26%
iShares Biotechnology ETFIBB9.61M0.09%10.4B USD0.44%$203.34+0.12%
Schwab U.S. Small-Cap ETFSCHA8.21M0.04%22.01B USD0.03%$32.61-1.47%
State Street SPDR S&P Pharmaceuticals ETFXPH7.94M1.63%462.1M USD0.35%$62.910.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P Pharmaceuticals ETFXPHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
